Easy-to-use kits require fewer manual steps,
reducing hands-on time and risk for error.
The development of recombinant therapeutic IgG is often challenging, including multiple candidates per program, reagent selection and limited sample volume. Added to that, the efficacy and safety parameters of lead candidates must be evaluated in two pre-clinical species, such as mouse, rat and cynomolgus monkey. Sample volumes may be limited and analyte levels may vary greatly.
To meet these needs, Gyros Protein Technologies has developed two kits for pharmacokinetics/toxicokinetics studies that accurately and robustly quantify human IgG1, IgG2, or IgG4 titer over broad ranges in a number of matrices and with the convenience that ready-to-use kits brings. The kits are based on the same reagents and compatible with two different Bioaffy CDs to deliver a combined dynamic range of five logs.
An additional benefit of Gyrolab technology is that an assay only consumes nanoliter volumes, which provides major benefits in preclinical work by enabling serial sampling of fewer mice to generate better data for more analyses and using less material.
The sandwich assay is based on biotinylated anti-human IgG-Fc as capturing molecule and fluorescently labeled monkey adsorbed anti-human IgG as detection antibody. The biotinylated reagent is captured in a streptavidin column in a microstructure in the CD. Diluted sera containing intact human IgG are volume-defined and introduced into the microstructures where intact IgG is captured on the capture column and the detection reagent is added.
For more information please contact your local sales or field application specialist.